RGO.F Regeneron Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
874.46 EUR
Close of Nov 12, 2026
507.29 868.00
Market cap
EUR 88.9B
P/E
22.1x
P/B
2.96x
ROE
15.8%
Dividend yield
0.41%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RGO.F undervalued?

Graham number
Price874.46
Graham value513.15
Premium70.4%

RGO.F trades 70.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regeneron Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Regeneron Pharmaceuticals Inc yet.

Regeneron Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic r…

Full company profile